Background: To improve our understanding of urea cycle disorders (UCDs) prospectively followed by two North American (NA) and European (EU) patient cohorts. Aims: Description of the NA and EU patient samples and investigation of the prospects of combined and comparative analyses for individuals with UCDs. Methods: Retrieval and comparison of the data from 1095 individuals (NA: 620, EU: 475) from two electronic databases.
| INTRODUCTION
The Urea Cycle Disorders Consortium (UCDC) was founded by the National Institutes of Health in 2003 in the United States as part of the Rare Diseases Clinical Research Network (http://www.rarediseasesnetwork.org/cms/UCDC). The European registry and network for Intoxication type Metabolic Diseases (E-IMD) was established in 2011 (http:// www.e-imd.org), funded by the European Union from 1st January 2011 to 30th April 2014 in the framework of the Health Programme 2008-2013 and later on by mixed funding sources (for details see the "Acknowledgements" section). Descriptions of the research networks have been published previously. [1] [2] [3] The objective of both projects is to improve knowledge on the natural history, treatment and outcome of urea cycle disorders (UCDs) by collecting longitudinal data on clinical, biochemical and treatment parameters, to foster training for families and professionals, and to develop evidence-based recommendations for six enzymopathies, i.e. deficiencies of N-acetylglutamate synthase (NAGS-D; OMIM #237310), carbamyl phosphate synthetase 1 (CPS1-D; OMIM #237300), ornithine transcarbamylase (OTC-D; OMIM #311250), argininosuccinate synthetase (ASS-D; OMIM #215700), argininosuccinate lyase (ASL-D; OMIM #207900) and arginase 1 (ARG1-D; OMIM #207800), and two transporter defects, i.e. deficiencies of the citrin or aspartate/glutamate carrier (CITR-D; OMIM #603471 and #605814; UCDC only) and the mitochondrial ornithine transporter 1 causing hyperornithinemia-hyperammonemiahomocitrullinuria syndrome (HHH syndr.; OMIM #238970).
The estimated cumulative prevalence of UCDs has been reported as 1 in 52,000−35,000 newborns. [4] [5] [6] Based on large data samples, several UCDC and E-IMD research projects have been published previously. 1, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] The aim of the present study was to investigate the similarities and differences in North American (NA) and European (EU) UCD samples from both registries, and to demonstrate how data can be combined to answer specific research questions. In particular, we analysed age at onset of symptoms and age at diagnosis, changes in modes of diagnoses over time, computed risks for early (EO) and late disease onset (LO) in individuals diagnosed early and treated pre-symptomatically, and used data from the E-IMD to describe the phenotype of signs and symptoms at the time of diagnosis.
| PATIENTS AND METHODS
Written informed consent was obtained from all participants before enrolment in the study and the baseline visit in countries where this was legally required. Patients who died before the starting date of the E-IMD (1st January 2011) are not recorded in the registry. Data were retrieved from the respective electronic databases with cut-off dates for the E-IMD sample at 16th March 2015 to allow for comparability with a previous publication 17 and 16th January 2016 for the UCDC sample. The UCDC database includes data from European research sites in Zurich and Heidelberg. For a transatlantic comparison, subjects from Heidelberg and Zurich enrolled in both registries or only in the UCDC were assigned to the EU sample.
| Commonalities and differences of the UCDC and E-IMD registries
Both registries use remote data entry via electronic forms comprising clinical and biochemical data regarding diagnosis and treatment from baseline, regular follow-up and emergency visits. The UCDC data model comprises about 570 variables and the E-IMD registry 490 variables, with an overlapping set of 258 variables. The disjoint sets mostly contain specifications of variables in the overlapping set. For example, the UCDC collects medical history data prior to study enrolment in more detail than the E-IMD, whereas metabolic emergencies are recorded in greater detail by the E-IMD. Furthermore, some common variables were measured on different levels (e.g. medication with or without dosage information). Both studies collect data about intellectual development and quality of life, with the UCDC dataset containing more formal neurocognitive testing details. Variables and values analysed in the present study are summarised in Table 1 .
| Statistical analysis
The R environment for statistical computing (2016) was used for statistical and graphical computations. Frequencies were analysed with log-linear models using the vcd package for R. 18 Contingency data of two or more independent variables are visualised as mosaic plots and differences between observed and expected frequencies were computed as standardised Pearson residuals by the vcd package. Positive residuals indicate observed frequencies higher than expected and negative residuals indicate frequencies lower than expected under the null hypothesis that frequency distributions will not be associated with the independent variables. Pearson residuals are calculated as (observed − expected)/ SQRT (expected) and can be interpreted as z-scores with residuals greater than 2 and less than −2 to be statistically significant at the 95% level. Examples are discussed in the Results section. Frequency distributions were compared with chi-square tests, and two-and three-way analyses of frequencies were tested with log-linear models. Ages at first symptoms and at diagnosis, diagnostic delays (age at diagnosis minus age at first symptoms) for onset types (EO versus LO), geographic regions (NA versus EU) and diseases were analysed with 3-way analysis of variance (ANOVA). Differences between means were tested with t-tests and differences between medians with the Wilcoxon ranksum test. Table 2 ). Due to the higher proportion of fOTC-D, in the NA sample, two-thirds are female and one-third is male, whereas the distribution of sexes is more balanced in the EU sample ( Table 2 Were in the adult age groups, while those in EU were in the paediatric age group, recognising that the samples are relatively small (Table 3 ). Accordingly, the median age at last visit was higher in NA than in EU (p < 0.001). Fatal disease was observed in 59 patients (6% from the NA and 4.6% from the EU samples), most of whom were mOTC-D (NA: 62.2%; EU: 63.3%) and died in the neonatal period (Table 3 ). Both registries included subjects who were enrolled post-mortem, as well as those who were alive at enrolment but died during the study (NA = 7, EU = 2). Taking into account the different time spans of the two studies (UCDC = 14 years, E-IMD = 5 years), the annual death rate in both datasets was about equal (7 patients in 14 years vs. 2 patients in 5 years).
Proportions of patients with EO (NA, EU: 23.2%, 26.4%) and LO for first symptoms (NA, EU: 42.6%, 43.3%) were similar in both registries (Table 2) . Asymptomatic individuals were 1.8 times more frequent in the UCDC than in the E-IMD database (NA, EU: 29.6%, 16.4%); however, onset information was not available for 24 individuals (4.5%) in the NA and 62 (13.9%) in the EU samples. Figure 2 shows the mosaic plot of the association of diagnoses, onset and geographical region. The time at onset showed a significant disease-specific pattern (p < 0.001, log-linear model); in both datasets, the most frequent disorders presenting with EO were ASS-D, ASL-D and mOTC-D, while fOTC-D and 
HHH syndr. and NAGS-D (NA, EU: 0, 1). For all diagnoses except ARG1-D, the age at diagnosis was similar for EO subjects in both datasets. The age at diagnosis was similar for all diagnoses in LO subjects, but not for asymptomatic individuals, for whom, except for OTC-D, ASS-D and ASL-D, the numbers were very small (for details, see Supplementary Figure 1 , Table 3 ). The triple interaction of the ANOVA of the mean age at diagnosis by geographic region, onset type and disease was not significant (p = 0.87), indicating similar patterns in both databases. The age at first symptoms was homogeneous in EO patients across diseases within a very short time window during the first 10 days of life and in LO patients by the end of the second year of life. Due to large differences in age at first symptoms between NA and EU in patients with LO NAGS-D, CPS1-D or HHH syndr. (Supplementary Figure 2,  Table 3 ), the interaction of geographic region with disease and onset type showed a trend (p = 0.064, ANOVA).
For diagnostic delay, the interaction of age of onset with mode of diagnosis was significant (p = 0.03). Delay was more similar in EO patients (PT: mean = − 1.13 days, 
| Mode of diagnosis and its change over time
Ranking modes of diagnosis resulted in the same order in both samples from SX being the most frequent to FH, NBS and PT (Table 2, Figure 3) . Starting with the year 1971, dividing the observation period into intervals of 10 years revealed that PT began in the 1980s and NBS in the mid1990s. While PT exceeded 5% only once (between 1981 and 1990), the proportion of NBS increased continuously. SX and FH remained the dominant modes of diagnosis in all decades.
| Confirmation of suspected UCDs in North America and Europe
Suspected diagnoses were confirmed by the analysis of metabolites, enzyme activity or mutations, by combinations of these methods or by pedigree analysis (Supplementary  Table 2 ). Methods were classified into five groups: (1) 
| Early diagnosis, pre-symptomatic diagnosis and onset type
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| Clinical phenotype of EO and LO patients at the time of diagnosis
Data from 111 EO patients and 130 LO patients revealed nine signs and symptoms at the time of their first clinical presentation (Supplementary Table 3 The correlation between numbers of signs and symptoms and plasma ammonium concentrations was significant in EO (r = 0.37, t = 3.8, df = 86, p < 0.001) but not in LO patients (r = 0.08, t = 0.84, df = 98, p < 0.4). In both onset groups, for each sign or symptom, t-tests were computed for differences of plasma ammonium concentrations in patients showing versus not showing a particular sign or symptom. Differences were significant for sepsis-like appearance (t = − 3.03, df = 84.6, p-value =0.003) and seizures (t = − 3.35, df = 48.4, p-value = 0.002) only for EO subjects. The mean plasma ammonium concentration for 24 individuals with both signs was 1520 μmol/L (SD = 1085); however, even patients without both signs still had a mean ammonium concentration of 577 μmol/L (SD = 423). In LO, only impaired consciousness showed a trend for patients with this sign having slightly higher plasma ammonium concentrations (mean = 290 μmol/L, SD = 246, n = 73) than those without this sign (mean = 218 μmol/L, SD = 2157, n = 27, t = − 1.7, df = 73.4, p < 0.09).
| DISCUSSION
The analysis of 1095 individuals with a UCD diagnosis from the UCDC and E-IMD registries revealed six results.
(1) As published previously, 3 OTC-D was the most frequent diagnosis in both samples. The case mixes in NA and EU differed due to the higher frequency of fOTC-D patients, particularly asfOTC-D, in NA. The exclusion of asfOTC-D allows to combine both registries into a common analysis. The higher rate of asfOTC-D in the NA sample is due to the explicit aim of the UCDC to investigate asymptomatic females. (2) Proportions of patients with LO were higher than of those with EO in both samples, highlighting that either LO is more and EO is less frequent than previously assumed or that patients with EO, the more severe phenotype, may have been less likely to be enrolled due to early death or may even have died without a diagnosis. Overall, death seems to be underreported when compared to the literature. 5, 19 Nine individuals died during the study; however, the annual death rates were similar. (3) Disease-specific age at diagnosis and diagnostic delay were similar in both samples. Delay was particularly long for ultra-rare UCDs (NAGS-D, ARG1-D) and rare clinical presentations (EO fOTC-D). (4) Modes of diagnosis changed over time following technological development. (5) Although only 26% of patients diagnosed during the first 10 days of life were asymptomatic at the time of diagnosis, 52% of them remained asymptomatic until the last visit. (6) At the time of diagnosis, EO and LO patients presented with a variety of non-specific signs and symptoms. In EO patients, only sepsis-like appearance and seizures were associated with peak plasma ammonium concentrations, whereas in LO patients, no association was found.
| Disease onset
Despite strong efforts having been made by both consortia to increase the proportion of patients with EO, 8 in both samples, EO was less frequently reported than LO. This is in agreement with previous results from the UCDC and E-IMD registries, 1,2,20 but in contrast to other studies showing a predominance of EO patients. 5, 21 As both registries are based on voluntary participation, it might be more arduous for individuals with EO and, thus, a more severe clinical phenotype to participate. Moreover, UCD patients with EO have a high risk of neonatal mortality. 5, 19 Therefore, many of these patients may have died without having an appropriate diagnosis or in hospitals not participating in the E-IMD and UCDC registries. Finally, the study design of the E-IMD excludes UCD patients who died before the year 2011. LO patients may benefit from NBS and PT, whereas the impact on patients with EO remains to be elucidated, since only a small proportion can be diagnosed before the appearance of first symptoms (in our dataset, symptoms preceded NBS diagnosis by 1.41 days). This is in line with a recent E-IMD study. 17 Importantly, 81% of patients diagnosed during the first 10 days of life had an EO. This should be considered for the establishment of NBS programmes. A higher proportion of EO patients can only be identified presymptomatically when NBS samples will be taken very early and processed very quickly. But even then, some EO patients will show first symptoms before the NBS result is available. About half of patients diagnosed before the onset of first symptoms during the neonatal period remained asymptomatic during the study period, and a substantial number of LO patients would also have benefited from presymptomatic identification by NBS.
| Clinical phenotypes of EO and LO patients at the time of diagnosis
The initial clinical phenotype of UCD patients is important for early diagnosis and was previously described. [21] [22] [23] [24] The most common initial symptoms of UCD patients are: (1) neurological (decreased level of consciousness, abnormal motor function, seizures), (2) gastrointestinal (vomiting, poor feeding), (3) psychiatric (hallucinations, personality changes) in older individuals, and (4) sepsis-like picture, particularly in neonates. These signs and symptoms are potentially triggered by catabolism (e.g. infections) or high protein load. Most patients presented with combinations of two (LO) or three (EO) symptoms. In LO subjects, plasma ammonium concentrations were comparatively low. They were neither correlated with the number of signs and symptoms nor with any particular sign, indicating a non-specific phenotype. In contrast, the plasma ammonium concentrations in EO subjects were significantly higher and correlated with the number of signs and symptoms. A sepsis-like appearance in combination with seizures was associated with a particularly severe metabolic phenotype. The specificities of single symptoms are low, but it remains to be tested whether combinations of symptoms are more predictive.
| CONCLUSION
Combined and comparative analysis of observational registries for patient with rare disorders such as urea cycle disorders (UCDs) can be an important research strategy. We described differences and similarities in the Urea Cycle Disorders Consortium (UCDC) and European registry and network for Intoxication type Metabolic Diseases (E-IMD) databases, the two largest studies of UDC patients. Differences, such as the ages of patients, can be used to increase age ranges in cross-sectional developmental studies, and different cohorts allow the investigation of historical trends in clinical practice. Similarities allow increased sample sizes and statistical power, or even the design of new studies. The example of females with ornithine transcarbamylase deficiency (fOTC-D) has shown that careful attention must be paid to the case mixes of different datasets to ensure that comparisons reflect true differences and not ascertainment bias. We have shown how this issue can be managed. The analysis of early and pre-symptomatically diagnosed subjects as a model for newborn screening (NBS) has also demonstrated that targeted evaluation of subsets of large combined datasets can be a promising strategy.
| Outlook
Based on this data analysis of the combination of two large UCD datasets, in-depth studies on specific questions regarding practice and outcome in UCDs are underway, including evaluation of treatment modalities, feasibility and efficacy of NBS programmes, and effects of liver transplantation and cognitive function in UCDs.
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